Burstein, R., N. J. Henry, M. L. Collison, L. B. Marczak, A. Sligar, S. Watson, N. Marquez, M. Abbasalizad-Farhangi, M. Abbasi, F. Abd-Allah, et al.,
"Mapping 123 million neonatal, infant and child deaths between 2000 and 2017",
Nature, vol. 574, no. 7778: Springer Science and Business Media LLC, pp. 353–358, oct, 2019.
AbstractSince 2000, many countries have achieved considerable success in improving child survival, but localized progress remains unclear. To inform efforts towards United Nations Sustainable Development Goal 3.2-to end preventable child deaths by 2030-we need consistently estimated data at the subnational level regarding child mortality rates and trends. Here we quantified, for the period 2000-2017, the subnational variation in mortality rates and number of deaths of neonates, infants and children under 5 years of age within 99 low- and middle-income countries using a geostatistical survival model. We estimated that 32% of children under 5 in these countries lived in districts that had attained rates of 25 or fewer child deaths per 1,000 live births by 2017, and that 58% of child deaths between 2000 and 2017 in these countries could have been averted in the absence of geographical inequality. This study enables the identification of high-mortality clusters, patterns of progress and geographical inequalities to inform appropriate investments and implementations that will help to improve the health of all populations.
Ye, R., M. Pi, M. M. Nooh, S. W. Bahout, and D. L. Quarles,
"Human GPRC6A Mediates Testosterone-Induced Mitogen-Activated Protein Kinases and mTORC1 Signaling in Prostate Cancer Cells.",
Molecular pharmacology, vol. 95, issue 5, pp. 563-572, 2019 05.
AbstractG protein-coupled receptor family C group 6 member A (GPRC6A) is activated by testosterone and modulates prostate cancer progression. Most humans have a GPRC6A variant that contains a recently evolved KGKY insertion/deletion in the third intracellular loop (ICL3) (designated as GPRC6A) that replaces the ancestral KGRKLP sequence (GPRC6A) present in all other species. In vitro assays purport that human GPRC6A is retained intracellularly and lacks function. These findings contrast with ligand-dependent activation and coupling to mammalian target of rapamycin complex 1 (mTORC1) signaling of endogenous human GPRC6A in PC-3 cells. To understand these discrepant results, we expressed mouse (mGPRC6A), human (hGPRC6A), and humanized mouse (mGPRC6A) GPRC6A into human embryonic kidney 293 cells. Our results demonstrate that mGPRC6A acts as a classic G protein-coupled receptor, which is expressed at the cell membrane and internalizes in response to ligand activation by testosterone. In contrast, hGPRC6A and humanized mouse mGPRC6A are retained intracellularly in ligand naive cells, yet exhibit -arrestin-dependent signaling responses, mitogen-activated protein kinase [i.e., extracellular signal-regulated kinase (ERK)], and p70S6 kinase phosphorylation in response to testosterone, indicating that hGPRC6A is functional. Indeed, testosterone stimulates time- and dose-dependent activation of ERK, protein kinase B, and mTORC1 signaling in wild-type PC-3 cells that express endogenous GPRC6A In addition, testosterone stimulates GPRC6A-dependent cell proliferation in wild-type PC-3 cells and inhibits autophagy by activating mTORC1 effectors eukaryotic translation initiation factor 4E binding protein 1 and Unc-51 like autophagy activating kinase 1. Testosterone activation of GPRC6A has the obligate requirement for calcium in the incubation media. In contrast, in GPRC6A-deficient cells, the effect of testosterone to activate downstream signaling is abolished, indicating that human GPRC6A is required for mediating the effects of testosterone on cell proliferation and autophagy.
Ye, R., M. Pi, M. M. Nooh, S. W. Bahout, and D. L. Quarles,
"Human GPRC6A Mediates Testosterone-Induced Mitogen-Activated Protein Kinases and mTORC1 Signaling in Prostate Cancer Cells.",
Molecular pharmacology, vol. 95, issue 5, pp. 563-572, 2019 05.
AbstractG protein-coupled receptor family C group 6 member A (GPRC6A) is activated by testosterone and modulates prostate cancer progression. Most humans have a GPRC6A variant that contains a recently evolved KGKY insertion/deletion in the third intracellular loop (ICL3) (designated as GPRC6A) that replaces the ancestral KGRKLP sequence (GPRC6A) present in all other species. In vitro assays purport that human GPRC6A is retained intracellularly and lacks function. These findings contrast with ligand-dependent activation and coupling to mammalian target of rapamycin complex 1 (mTORC1) signaling of endogenous human GPRC6A in PC-3 cells. To understand these discrepant results, we expressed mouse (mGPRC6A), human (hGPRC6A), and humanized mouse (mGPRC6A) GPRC6A into human embryonic kidney 293 cells. Our results demonstrate that mGPRC6A acts as a classic G protein-coupled receptor, which is expressed at the cell membrane and internalizes in response to ligand activation by testosterone. In contrast, hGPRC6A and humanized mouse mGPRC6A are retained intracellularly in ligand naive cells, yet exhibit -arrestin-dependent signaling responses, mitogen-activated protein kinase [i.e., extracellular signal-regulated kinase (ERK)], and p70S6 kinase phosphorylation in response to testosterone, indicating that hGPRC6A is functional. Indeed, testosterone stimulates time- and dose-dependent activation of ERK, protein kinase B, and mTORC1 signaling in wild-type PC-3 cells that express endogenous GPRC6A In addition, testosterone stimulates GPRC6A-dependent cell proliferation in wild-type PC-3 cells and inhibits autophagy by activating mTORC1 effectors eukaryotic translation initiation factor 4E binding protein 1 and Unc-51 like autophagy activating kinase 1. Testosterone activation of GPRC6A has the obligate requirement for calcium in the incubation media. In contrast, in GPRC6A-deficient cells, the effect of testosterone to activate downstream signaling is abolished, indicating that human GPRC6A is required for mediating the effects of testosterone on cell proliferation and autophagy.
Frank, T. D., A. Carter, D. Jahagirdar, M. H. Biehl, D. Douwes-Schultz, S. L. Larson, M. Arora, L. Dwyer-Lindgren, K. M. Steuben, H. Abbastabar, et al.,
"Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017",
The Lancet HIVThe Lancet HIV, vol. 6, issue 12: Elsevier, pp. e831 - e859, 2019.
AbstractBackgroundUnderstanding the patterns of HIV/AIDS epidemics is crucial to tracking and monitoring the progress of prevention and control efforts in countries. We provide a comprehensive assessment of the levels and trends of HIV/AIDS incidence, prevalence, mortality, and coverage of antiretroviral therapy (ART) for 1980?2017 and forecast these estimates to 2030 for 195 countries and territories.BackgroundUnderstanding the patterns of HIV/AIDS epidemics is crucial to tracking and monitoring the progress of prevention and control efforts in countries. We provide a comprehensive assessment of the levels and trends of HIV/AIDS incidence, prevalence, mortality, and coverage of antiretroviral therapy (ART) for 1980?2017 and forecast these estimates to 2030 for 195 countries and territories.
Cacoub, P., S. N. Si ahmed, Y. ferfar, S. Pol, D. Thabut, C. Hezode, L. Alric, C. Comarmond, G. Ragab, L. Quartuccio, et al.,
"Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus–Associated Cryoglobulinemia Vasculitis",
Clinical Gastroenterology and Hepatology, vol. 17, issue 3: W.B. Saunders, pp. 518 - 526, 2019.
Abstractn/a
Cacoub, P., S. Nafa Si Ahmed, Y. Ferfar, S. Pol, D. Thabut, G. Ragab, L. Quartuccio, M. T. Hegazy, T. Poynard, M. Resche Rigon, et al.,
"Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated Cryoglobulinemia Vasculitis",
Clinical Gastroenterology and Hepatology, vol. 3, issue 17, pp. 518-526, 05, 2019.
Abstract
Duvnjak, D., P. Jackson, J. L. Oliver, A. Petridis, A. Qureshi, A. S. Sharma, M. J. White, V. Jain, S. P. Swift, D. M. Gingrich, et al.,
"Combinations of single-top-quark production cross-section measurements and| f LV V tb| determinations at√ s= 7 and 8 TeV with the ATLAS and CMS experiments",
Journal of high energy physics, vol. 2019, no. 5: Institute of Physics and IOP Publishing Limited, pp. 88–88, 2019.
Abstractn/a
Chahal, A., M. Qasheesh, A. S. Shalaby, A. Shaphe, M. Hany, R. A. Beg, P. Chaudhuri, N. Malhotra, and J. Kirmani,
"A cumulative physiotherapy education program assessment in Jazan University: Need for a healthy society in Saudi Arabia. A Retrospective study",
ioscience Biotechnology Research Communication, vol. 12, issue 2, pp. 317-323, 2019.
Elbaz, T., M. Abdo, H. Omar, E. A. Hassan, A. M. Zaghloul, M. Abdel-Samiee, A. Moustafa, A. Qawzae, M. Gamil, and G. Esmat,
"Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection.",
Journal of medical virology, vol. 91, issue 2, pp. 272-277, 2019.
AbstractHepatitis C virus (HCV) infection is considered as a major public health problem that, worldwide, chronically affects 170 million people. Elderly patients are more likely than younger patients to have increased duration of infection, increased rate of disease progression, and subsequently increased incidence of advanced liver disease. Natural history models predicted that the prevalence of HCV infection and its chronic sequelae as well as extrahepatic manifestations will eventually increase through the next decade and will mostly affect those who are greater than 60 years of age. Moreover, polytherapy and polypharmacy are frequent in elderly patients due to associated comorbidities. As advanced age is associated with increasing risk of development of cirrhosis and hepatocellular carcinoma, elderly patients are in special need of safe and effective antiviral therapies. Achievement of sustained viral responses (SVR) is associated with reduced liver-related complications and overall mortality in such patients with the advanced liver disease. With the recent introduction of interferon-free direct-acting antivirals, successful treatment for chronic HCV infection had dramatically improved, with overall cure rates that exceed 90% SVR. In our study, we aimed to study the efficacy and safety of combined sofosbuvir and daclatasvir, with or without ribavirin, in management of chronically infected HCV elderly patients who are more than 60 years old.
Elbaz, T., M. Abdo, H. Omar, E. A. Hassan, A. M. Zaghloul, M. Abdel-Samiee, A. Moustafa, A. Qawzae, M. Gamil, and G. Esmat,
"Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection.",
Journal of medical virology, vol. 91, issue 2, pp. 272-277, 2019.
AbstractHepatitis C virus (HCV) infection is considered as a major public health problem that, worldwide, chronically affects 170 million people. Elderly patients are more likely than younger patients to have increased duration of infection, increased rate of disease progression, and subsequently increased incidence of advanced liver disease. Natural history models predicted that the prevalence of HCV infection and its chronic sequelae as well as extrahepatic manifestations will eventually increase through the next decade and will mostly affect those who are greater than 60 years of age. Moreover, polytherapy and polypharmacy are frequent in elderly patients due to associated comorbidities. As advanced age is associated with increasing risk of development of cirrhosis and hepatocellular carcinoma, elderly patients are in special need of safe and effective antiviral therapies. Achievement of sustained viral responses (SVR) is associated with reduced liver-related complications and overall mortality in such patients with the advanced liver disease. With the recent introduction of interferon-free direct-acting antivirals, successful treatment for chronic HCV infection had dramatically improved, with overall cure rates that exceed 90% SVR. In our study, we aimed to study the efficacy and safety of combined sofosbuvir and daclatasvir, with or without ribavirin, in management of chronically infected HCV elderly patients who are more than 60 years old.
Qi, X., Z. Li, M. Akami, A. Mansour, and C. Niu,
"Fermented crop straws by Trichoderma viride and Saccharomyces cerevisiae enhanced the bioconversion rate of Musca domestica (Diptera: Muscidae).",
Environmental science and pollution research international, vol. 26, issue 2019, pp. 29388–29396, 2019.
AbstractCrop straw is an abundant renewable resource whose usage is limited due to its high cellulose, hemicellulose, and lignin contents. Here, Trichoderma viride, Saccharomyces cerevisiae, and Musca domestica were used to transform crop straws, and we investigated their impact on housefly rearing performance and optimized their utilization. The weights of cellulose, hemicellulose, and lignin in fermented crop straw diets significantly decreased after bioconversion by M. domestica larvae. The highest bioconversion rate was recorded in corn straw diet (16.19%), followed by wheat straw diet (10.31%) and wheat bran diet (8.97%). Similarly, high larval weight (yield) and pupation rate and fecundity and fertility rate were recorded in fermented crop straw diets composed of corn straw and wheat bran in 1:1 proportions. These results indicated that fermenting crop straw with T. viride and S. cerevisiae represented an efficient strategy that enhanced crop straw bioconversion and improved the rearing capacity of the housefly larvae. The resulting larvae could further be used as proteinaceous feed in poultry and aquaculture industries. Graphical abstract.
Alsaedi, H., A. Prince, D. Quraishi, and M. Ali,
"Gene expression alterations in delayed wound healing in diabetic rats treatment of stem cells and platelet-rich plasma",
BIOCHEMICAL AND CELLULAR ARCHIVES, vol. 19, issue 1, pp. 1783-1790, 2019.
ALIBWEINI, M. S. M., M. Elkhedr, K. A. QAHMAN, H. M. Bekhit, and A. E. Hassan,
"GROUND WATER MANAGEMENT OF RAFAH COASTAL AQUIFER, PALESTINE",
Journal of Engineering and Applied Science, vol. 66, issue 6, pp. 815–835, 2019.
Salehi, B., J. Sharifi-Rad, C. Quispe, H. Llaique, M. Villalobos, A. Smeriglio, D. Trombetta, S. M. Ezzat,, Jouini R, and et al,
"Insights into Eucalyptus genus chemical constituents, biological activities and health-promoting effects",
Trends in Food Science & Technology, vol. 91, issue 2019, pp. 609-624, 2019.
Cacoub, P., S. Nafa Si Ahmed, Y. Ferfar, S. Pol, D. Thabut, C. Hezode, L. Alric, C. Comarmond, G. Ragab, and L. Quartuccio,
"Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus–Associated Cryoglobulinemia Vasculitis",
Clinical Gastroenterology and Hepatology, vol. 17, issue 3: WB Saunders, pp. 518-526, 2019.
Abstractn/a
Wang, K., L. Zhoua, S. Zhaoc, Z. Cheng, S. Qiua, Y. Lua, Z. Wua, A. H. A. A. Wahabd, and Hongj,
"A microfluidic platform for high-purity separating circulating tumor cells at the single-cell level",
talanta, vol. 200, pp. 169-176, 2019.